You must see it Van., This is fast zombie non of that slow shit. When you can outrun the bad guys, These Zombies are on you quick and they rip your face off!!! This move is by the directer who did Parasite. He is Fantastic Korean director. It really works. The sequel is terrible.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
Ideas For Now-
- Thread starter stonedinvestor
- Start date
You must see it Van., This is fast zombie non of that slow shit. When you can outrun the bad guys, These Zombies are on you quick and they rip your face off!!! This move is by the directer who did Parasite. He is Fantastic Korean director. It really works. The sequel is terrible.
Do we have a G0-Pro video of this one?Where have I been.. with all this GoPro going on. It's absolutely beautiful. The underwater stuff. I thought it was only for ATV's and trail bikes... What have I been missing. the glory of the deep blue sea.
He Wenna is a female Chinese trampoline gymnast. She won the gold medal in the 2008 Summer Olympics. She attracted people’s eyeballs not only for her sports performance but for her beautiful appearance.
#8 above.
Nasstassia says trampoline gymnasts think they're better than everyone else.
2021 PREDICTION GO PRO IS GOING TO $17!!!!!
What is going on with the virus.
New variant of virus is transferred between children more.
New Virus is here and that's why al these numbers are off the chart.
For the first time I heard a medical pro from a vaccine co say we could make another dose with the new variant in mind... It wouldn't take long at all. Yea but what about al the people who have the other one already? Would politics delay this...
Lastly there is a variant in South Africa that has people scared. That one may be more fatal.
New variant of virus is transferred between children more.
New Virus is here and that's why al these numbers are off the chart.
For the first time I heard a medical pro from a vaccine co say we could make another dose with the new variant in mind... It wouldn't take long at all. Yea but what about al the people who have the other one already? Would politics delay this...
Lastly there is a variant in South Africa that has people scared. That one may be more fatal.
XPeng call volume above normal and directionally bullish
VAN NOW!!!!
VAN NOW!!!!
Azek, Trex among Blair's top Specialty Distribution ideas for 2021
DECKS DECKS DECKS
DECKS DECKS DECKS
2021 PREDICTION $SJM WILL RETIRE THE FAMILY CEO AND BRING IN A WALL STREET SAVANT TO UNLOCK HUGE VALUE FOR THE GOOD OF THE SHAREHOLDERS!!!!!
Good lord that stock's a dog. And it shouldn't be!!!
We're keeping it in the G4G portfolio however, in the hopes some funds step up and urge Mr Smucker (age 72) to do the right thing and move to FL. Buy him a fishing boat, or golf clubs,... or something.
Good lord that stock's a dog. And it shouldn't be!!!
We're keeping it in the G4G portfolio however, in the hopes some funds step up and urge Mr Smucker (age 72) to do the right thing and move to FL. Buy him a fishing boat, or golf clubs,... or something.
e.l.f. Beauty rises 10.9%
SG Blocks launches COVID-19 testing at Los Angeles International Airport »? (SGBX)
Short seller Friendly Bear sees Lemonade falling '90%+ in short order' »
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform 11:03
ARCT
After Arcturus announced this morning its selection of a therapeutic candidate, ARCT-032, for the LUNAR-CF program, Piper Sandler analyst Yasmeen Rahimi noted that "bears may view this morning's announcement as a distraction from ARCT-021's COVID-19 program." However, Rahimi thinks the market has been "overreacting" to the neutralizing titer data from ARCT-021's Phase 1 update and continues to "strongly believe" in the company's mRNA technology platform, the analyst tells investors. Rahimi has an Overweight rating and $140 price target on Arcturus shares.
ARCT took a huge tumble and it was a Motley Fool favorite! A lot of angry fools out there but could there be smart money buying now? I wonder. I think probably. It's 50-50 but this name could double.
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg 07:18 ARCT, MRNA, PFE Ladenburg analyst Wangzhi Li said that a UK study of 2,826 healthcare and frontline workers with high exposure risk to COVID-19 shows "strong evidence" that T cell response alone in seronegative subjects could achieve complete protection from COVID-19 without antibody response, which the analyst points to as support for the view that there is a "good probability" that Arcturus Therapeutics' (ARCT) ARCT-021 can ultimately achieve "90+% protection efficacy" despite the latest ARCT-021 data update that raised questions about a lower titer of neutralizing antibody response. The analyst, who still sees a good probability for ARCT-021 to achieve efficacy close to that seen with the vaccines from Moderna (MRNA) and Pfizer (PFE), keeps a Buy rating and $123 price target on Arcturus shares.
SG Blocks launches COVID-19 testing at Los Angeles International Airport »? (SGBX)
Short seller Friendly Bear sees Lemonade falling '90%+ in short order' »
Piper says market 'overreacting' to Arcturus COVID data, sees value in platform 11:03
ARCT
After Arcturus announced this morning its selection of a therapeutic candidate, ARCT-032, for the LUNAR-CF program, Piper Sandler analyst Yasmeen Rahimi noted that "bears may view this morning's announcement as a distraction from ARCT-021's COVID-19 program." However, Rahimi thinks the market has been "overreacting" to the neutralizing titer data from ARCT-021's Phase 1 update and continues to "strongly believe" in the company's mRNA technology platform, the analyst tells investors. Rahimi has an Overweight rating and $140 price target on Arcturus shares.
ARCT took a huge tumble and it was a Motley Fool favorite! A lot of angry fools out there but could there be smart money buying now? I wonder. I think probably. It's 50-50 but this name could double.
UK study supports potential of Arcturus COVID vaccine candidate, says Ladenburg 07:18 ARCT, MRNA, PFE Ladenburg analyst Wangzhi Li said that a UK study of 2,826 healthcare and frontline workers with high exposure risk to COVID-19 shows "strong evidence" that T cell response alone in seronegative subjects could achieve complete protection from COVID-19 without antibody response, which the analyst points to as support for the view that there is a "good probability" that Arcturus Therapeutics' (ARCT) ARCT-021 can ultimately achieve "90+% protection efficacy" despite the latest ARCT-021 data update that raised questions about a lower titer of neutralizing antibody response. The analyst, who still sees a good probability for ARCT-021 to achieve efficacy close to that seen with the vaccines from Moderna (MRNA) and Pfizer (PFE), keeps a Buy rating and $123 price target on Arcturus shares.